MOMA-341 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called MOMA-341 for individuals with certain advanced or metastatic solid tumors that have specific genetic changes. Researchers aim to determine the safety and efficacy of MOMA-341, both alone and in combination with other treatments. They seek participants who have tried other cancer treatments without success and have solid tumors with specific genetic markers, such as MSI-H or dMMR, which relate to DNA repair. Individuals with solid tumors meeting these criteria and who have previously tried an anti-PD-(L)1 treatment may be suitable candidates for this trial. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering the opportunity to be among the first to receive this new therapy.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop your current medications. However, it mentions that you must be fully recovered from prior therapies, and hormonal therapy is allowed. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that MOMA-341 is being tested for safety in patients with certain advanced solid tumors. It is administered alone or with other treatments, such as chemotherapy and immunotherapy. In these early studies, MOMA-341 has demonstrated some ability to fight cancer cells.
Since it is still in early testing (Phase 1), the main goal is to assess its safety and tolerability. This involves checking for any side effects and understanding how the body processes the medicine. So far, no clear data on side effects have emerged from these studies. This phase focuses on ensuring it is safe for further testing.
In summary, MOMA-341 is in the early stages of safety testing. The focus remains on ensuring it is safe for patients, whether used alone or with other treatments.12345Why are researchers excited about this trial's treatments?
Researchers are excited about MOMA-341 for cancer because it offers a fresh approach compared to traditional treatments like chemotherapy and surgery. While most standard treatments attack cancer cells directly, often harming healthy cells in the process, MOMA-341 has a unique mechanism that potentially allows it to target cancer cells more precisely. This means it could minimize damage to healthy cells and reduce side effects. Additionally, MOMA-341's versatility is showcased in its combinations with immunotherapy and irinotecan, providing new avenues for enhancing treatment effectiveness.
What evidence suggests that this trial's treatments could be effective for cancer?
Research has shown that MOMA-341 may be promising for treating certain cancers with specific genetic features. In this trial, participants may receive MOMA-341 as a monotherapy, which lab studies have found to shrink tumors more effectively at higher doses. Another treatment arm involves MOMA-341 combined with chemotherapy, such as irinotecan, which increases DNA damage in cancer cells, making them more sensitive to treatment. Additionally, some participants will receive MOMA-341 with immunotherapy, potentially enhancing the immune system's ability to attack tumors. Although these findings are preliminary, they suggest that MOMA-341 could be useful for treating some hard-to-treat cancers.12367
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic solid tumors that are MSI-H or dMMR and have worsened after anti-PD-(L)1 therapy. If they can't take anti-PD-(L)1 due to autoimmune conditions, they're still eligible. Participants need at least one measurable tumor, an ECOG performance status of ≤2, recovered from past treatments (except hormonal), proper organ function, and must follow contraception rules.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive MOMA-341 as monotherapy or in combination with irinotecan or immunotherapy in dose-escalation and dose-optimization phases
Follow-up
Participants are monitored for safety, tolerability, and clinical activity after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- MOMA-341
Find a Clinic Near You
Who Is Running the Clinical Trial?
MOMA Therapeutics
Lead Sponsor